A detailed history of Parallel Advisors, LLC transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Parallel Advisors, LLC holds 13 shares of CPRX stock, worth $267. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13
Previous 13 -0.0%
Holding current value
$267
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

May 20, 2024

SELL
$11.69 - $15.02 $1,636 - $2,102
-140 Reduced 91.5%
13 $0
Q3 2023

Nov 13, 2023

SELL
$11.69 - $15.02 $1,636 - $2,102
-140 Reduced 91.5%
13 $0
Q1 2023

May 20, 2024

BUY
$14.34 - $21.05 $2,007 - $2,947
140 Added 1076.92%
153 $2,000
Q3 2022

Nov 10, 2022

BUY
$7.06 - $15.52 $1,080 - $2,374
153 New
153 $2,000
Q1 2021

Apr 23, 2021

SELL
$3.45 - $4.69 $6 - $9
-2 Closed
0 $0
Q4 2020

Feb 02, 2021

BUY
$2.97 - $3.83 $5 - $7
2 New
2 $0

Others Institutions Holding CPRX

About CATALYST PHARMACEUTICALS, INC.


  • Ticker CPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 102,820,000
  • Market Cap $2.12B
  • Description
  • Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...
More about CPRX
Track This Portfolio

Track Parallel Advisors, LLC Portfolio

Follow Parallel Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.